 NEW YORK, April 26, 2022 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS diseases, today announced that Christopher U Missling, PhD, President Chief Executive Officer of Anavex will present at the B. Riley Securities 2022 Virtual Neuro Ophthalmology Conference on Wednesday, April 27, 2022, at 11:00 AM ET. 